1. Academic Validation
  2. Donor-Acceptor-Donor Strategy Rouses the Photodynamic Therapy Anticancer Activity of a Bis-terpyridyl Ru(II) Complex

Donor-Acceptor-Donor Strategy Rouses the Photodynamic Therapy Anticancer Activity of a Bis-terpyridyl Ru(II) Complex

  • J Med Chem. 2024 Aug 8;67(15):13435-13445. doi: 10.1021/acs.jmedchem.4c01307.
Zhongyu Wang 1 2 Li Wei 2 Junfeng Lin 2 3 Can Huang 3 Huitong Chen 1 Dong Fan 1 Weiyu Hu 4 Jing Liu 1 Huaiyi Huang 2 Zongming Wang 4 Xin Wang 1
Affiliations

Affiliations

  • 1 School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, P.R China.
  • 2 School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong 518107, P.R China.
  • 3 Department of Pharmacy, Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong 518107, P.R China.
  • 4 Department of Neurosurgery and Pituitary Tumor Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R China.
Abstract

Photodynamic therapy has been regarded as a noninvasive treatment for Cancer with spatiotemporal control over drug activation. Bis-terpyridyl Ru(II) complexes exhibit a promising achiral structure but suffer from low photoreactivity due to deviation from the ideal octahedral geometry. Herein, we introduce the donor-acceptor-donor motif to construct a dinuclear bis-terpyridyl Ru(II) complex (Ru2). Ru2 exhibits superior LIGHT absorption properties compared with mononuclear complex Ru1. Importantly, upon 595 nm LIGHT excitation, Ru2 shows promising synergetic type I/II photosensitization and photocatalytic activity, while Ru1 is inactive. Anticancer mechanistic studies reflect that Ru2 induces intracellular redox imbalance and affects the biosynthetic and metabolic processes, leading to cell Apoptosis. Overall, this work provides a simple strategy to rouse the PDT efficiency of bis-terpyridyl Ru(II) complexes.

Figures
Products